Prognostic Significance of MGMT Promoter Methylation in Patients with Glioblastoma Undergoing Surgical Intervention: A Retrospective Study in Northeastern Iran
Journal Title: Middle East Journal of Cancer - Year 2018, Vol 9, Issue 3
Abstract
Background: The standard of care for glioblastoma is concurrent chemoradiotherapy and adjuvant chemotherapy with Temozolomide. In this trial, we have investigated the impact of MGMT promoter methylation on prognosis and benefit from Temozolomide based chemotherapy in a group of patients with glioblastoma in our region. Methods: This retrospective study included glioblastoma patients treated in our institute between 2006 and 2011. We used methylation specific PCR to detect methylation in the promoter region of the MGMT gene. The Kaplan-Meier technique was used to calculate overall survival from the time of diagnosis to the time of death. We utilized the log-rank test and Cox-regression model for univariate and multivariate analyses of potential prognostic factors. Results: There were 78 patient participants with a median age of 50 (range: 20 to 75) years and a male to female ratio of 56/22. All patients underwent minimal surgical resection which was considered as a biopsy. All patients received adjuvant radiotherapy with a median dose of 60 Gy (54-60 Gy) and 25 patients received concomitant Temozolomide. The MGMT promoter methylation was found in 19 (24.4%) patients and was relatively more frequent in men (28.6%) compared to women (13.6%; P=0.16).This genetic change was associated with a significantly higher 2-year survival in men (57.2%) compared to women (16.8%; P<0.001). Multivariate analysis indicated that male sex and MGMT promoter methylation were independently associated with more favorable prognosis. Conclusion: In our series, MGMT promoter methylation was a significant independent prognostic factor. The finding of sex as an independent prognostic factor would need further validation.
Authors and Affiliations
Kazem Anvari, Mehdi Seilanian Toussi, Hossein Ayatollahi, Gholamreza Bahadorkhan, Mohammadreza Ghavam Nasiri, Mitra Fazl Ersi
Keywords
Related Articles
- EP ID EP303062
- DOI -
- Views 87
- Downloads 0
Non-Hodgkin’s Lymphoma Mimicking a Locally Advanced Renal Mass: A Case Report
Renal masses can be categorized as benign and malignant lesions. Among the renal malignancies, renal cell carcinoma is the most common malignancy. However, other rare malignant lesions should be considered in differentia...
Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
Background: Metastatic prostate cancer is one of the most important cancers among men worldwide. Androgen ablation therapy can be used in treatment of these patients; however, most will progress to metastatic hormone-ref...
Epidemiology and Cost of Patients with Cancer in Iran: 2018
Background: Third leading cause of mortality in the world is cancer, with more than 12 million new cases and nearly 7.6 million deaths in 2007. The time estimation of healthcare costs of patients with cancer is an import...
Efficacy of Phenytoin Mucoadhesive Tablet versus Mouthwash on Chemotherapy-Induced Oral Mucositis: A Randomized Clinical Trial
Background: Oral mucositis is one of the painful, debilitating and common complications in the patients under chemotherapy for which no certain and effective treatment has not been considered. The aim of this pilot study...
Investigation of Programmed Cell Death-1 (PD-1) Gene Variations at Positions PD1.3 and PD1.5 in Iranian Patients with Non-small Cell Lung Cancer
Background: Tumor cells express PD-1 ligands to bind PD-1 on immune cells and escape immune responses. In the present study, we aimed to investigate whether single nucleotide polymorphisms at positions PD1.3 (+7146, rs11...